GERN Geron Corp

XNAS 1.13 Delayed
Find condors

Stock quote, options chain, IV rank, technicals, AI analysis, and institutional ownership. Iron condor setups Expected move IV rank history Fibonacci levels Insider trading

Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.

GERN $1.13 —
Key stats
$1.13
52-Week Range
$1.04 – $2.01
YTD
-14.39%
IV Rank (30D)
29.39
Straddle Price
$0.28
P/C Vol Ratio
0.08
Market Cap
$0.7B
Open
$1.16
Day Range
$1.12 – $1.19
Volume
7,178,600
Prev Close
$1.16
Fair Value
MODEL: LONG

A blended fair-value estimate combining up to six valuation methods. Each method is weighted by how well it fits the company — DCF down-weights for unprofitable names; DDM only fires for steady dividend payers; comparables down-weight when peer multiples disagree.

  • DCF (quality-aware) — projects free cash flow with a horizon that scales to business quality. True compounders (quality 6/6) get 10 years explicit + 10 years fade before terminal; cyclical/struggling names (quality 0-1) get a 5-year terminal cliff. Quality is scored from ROE, gross margin, growth, FCF margin, debt load, and FCF consistency — the same factors that drive market premium for compounders.
  • Market-Implied Growth (in Model Inputs) — reverse-DCF that answers "what growth rate is the market pricing in?". Lets you sanity-check the deviation: if implied growth is plausible for the business, the model's bearish flag may be wrong; if implausible, the market may be over-extrapolating.
  • DDM (Gordon Growth Dividend Model) — values the stream of future dividends. Only used when trailing yield ≥ 2% and dividend payments are stable — below that the dividend is a token payout and Gordon (which values only the dividend stream) systematically underprices growth names, so those route to DCF + comparables + market anchor instead.
  • P/E, EV/EBITDA, P/B, P/S — applies the peer-group median multiple to this company's per-share metric. Peers come from the same set as the "Related symbols" card. Earnings/sales metrics are forward-tilted by the company's recent revenue growth (capped at 25%) so they're comparable to peers' growth-embedded multiples — mimics how analysts use NTM rather than TTM. Per-multiple weights are biased by company quality (e.g. P/B down-weighted for asset-light tech).
  • Market Anchor (SMA50) — the 50-day moving average, weighted by recent trading-range stability (tighter Bollinger bands → higher weight). Captures information fundamentals miss (forward consensus, sentiment, supply/demand) — but only when recent trading is steady enough that the market has converged on a view. During wild breakouts or breakdowns the anchor's weight collapses.
  • Options Expected (B-L 30d) — the risk-neutral expected stock price at 30-day options expiration, derived from the full implied-volatility surface via Breeden-Litzenberger (second derivative of call price wrt strike → implied PDF, then E[S_T]). Forward-looking, captures all options-implied information (smile, skew, term structure) in one number. Weighted by chain liquidity. SP500-only at present (pre-computed daily). Backtest evidence: adds modest alpha across most bucket × holding combos.
  • Blended value — weighted average. Confidence reflects how many methods fired and how tight peer dispersion is.
  • Deviation pill — green when blended FV ≥ 10% above current price (undervalued); red when ≥ 10% below; grey otherwise.
10-yr Treasury (rf)5.15%
Beta vs SPY1.05
Cost of Equity (CAPM)10.94% (VRP-adj)
WACC9.70%
Volatility Risk Premium+199.5pp (IV − HV30), ERP adj +50bps
Effective Tax Rate21.0%
Rev. Growth (YoY, DCF input)+21.7%
DCF Horizon10 years explicit + fade
Forward Tilt (NTM/TTM)×1.10 (applied to P/E, EV/EBITDA, P/S)
Free Cash Flow (TTM)$-0.1B
Return on Equity (TTM)-30.9%
Book / Price28.2%
Gross Margin (TTM)94.7%
FCF Margin (TTM)-56.1%
Debt / Equity1.05
Quality Score2/6 — normal (10y DCF)
SMA 50$1.36 (Market Anchor value)
SMA 20 / Bollinger Mid$1.22
Bollinger Width / SMA20708.8% (drives anchor stability)
Net Debt$0.2B
Market Cap$1B
Peers used for multiples: ACAD, AGIO, AMGN, CRNX, MIRM, MRNA, REGN, TVTX
60-Day Conviction
95%
20-Day Fair Value
≈ by Nov 20, 2026
$1.13
α +0.4% rank 93%
conviction
25%
40-Day Fair Value
≈ by Dec 21, 2026
$1.16
α +2.5% rank 94%
conviction
75%
60-Day Fair Value
≈ by Jan 19, 2027
$1.19
α +5.0% rank 92%
conviction
95%
MethodImplied PriceWeightDetail
DCF n/a 0%
DDM (Gordon) n/a 0%
Peer P/E n/a 0% median 19.2× · 3 peers
Peer EV/EBITDA n/a 0% median 26.4× · 4 peers
Peer P/B $2.47 17% median 7.6× · 7 peers
Peer P/S $2.91 17% median 8.6× · 8 peers
Market Anchor (SMA50) $1.36 65% stability 73% (BB-width)
Options Expected (B-L 30d) n/a 0%
As of 2026-10-22 · updated
About
Industry (SIC)
PHARMACEUTICAL PREPARATIONS (2834) · industry map
Exchange
XNAS
Market Cap
$0.7B
Employees
258
List Date
1996-07-31
CIK
0000886744
Next Earnings
2026-11-04 (Pre-Market)
EPS Forecast
($0.01) (4 est.)
Headquarters
Foster City, CA
Homepage
https://www.geron.com

Geron Corp is a biopharmaceutical company focused on blood cancers. Its telomerase inhibitor, RYTELO (imetelstat), is approved in the United States and European Union for certain adult patients with lower-risk myelodysplastic syndromes (LR-MDS) with transfusion-dependent anemia. RYTELO inhibits telomerase activity in malignant stem and progenitor cells, which may reduce abnormal cell proliferation while supporting the production of healthy cells. It is also conducting a Phase 3 trial of imetelstat in patients with JAK-inhibitor-refractory or relapsed myelofibrosis (R/R MF) and studies in other…

Summary
—
composite
—
No summary data available for this symbol yet.

Each spoke is this symbol's rank within its sector (0–100; the dotted ring marks the sector median at 50). Higher is more constructive for a long. One spoke — News sentiment — is an absolute reading, not a sector rank. Grayed spokes have no data. A fuller shape is a summary, not a recommendation.

Chart
Seasonality
'21'22'23'24'25'26Avg
Jan9.20%-14.50%37.50%-14.02%-20.28%3.79%0.28%
Feb-5.79%0.00%-17.75%4.17%-38.25%9.09%-8.09%
Mar-15.05%27.10%-21.94%46.02%-7.02%-3.87%4.21%
Apr-10.49%-7.24%13.36%23.97%-4.73%-7.23%1.27%
May-3.50%-7.38%27.73%-12.99%6.29%-20.89%-1.79%
Jun0.71%16.54%-5.03%10.70%-1.40%5.79%4.55%
Jul-17.01%13.77%1.89%9.22%-16.67%1.57%-1.21%
Aug16.00%41.94%-24.30%-0.63%19.66%16.41%11.51%
Sep-6.16%-12.69%-14.52%3.18%-6.80%-16.89%-8.98%
Oct11.59%-6.33%-4.52%-6.80%-10.64%-6.61%*-3.89%
Nov-5.73%7.91%0.00%0.24%-1.67%--0.15%
Dec-11.59%8.04%6.03%-12.38%10.92%--0.20%
Total-36.13%67.53%-18.97%43.15%-58.61%-22.45%-4.24%
Technical Indicators

Quick-reference for reading the values below. Indicators combine to confirm a view — no single one is a trade signal on its own.

Trend Indicators
  • SMA 20 / 50 / 200 — price above = uptrend, below = downtrend. SMA 50 crossing SMA 200 is the golden/death cross.
  • EMA 12 / 26 — faster-reacting averages; 12 above 26 is short-term bullish.
  • MACD — bullish when MACD > signal (green badge), bearish when below. Divergence from price often precedes reversals.
  • ADX (14) — trend strength regardless of direction. <20 range, 20–25 weak trend, 25–50 trend, >50 strong trend.
  • +DI / −DI — +DI > −DI favors bulls; the reverse favors bears. Read alongside ADX.
Momentum Oscillators
  • RSI (14) — <30 oversold, >70 overbought. 40–60 is neutral; trending names can stay extreme.
  • Stochastic %K / %D — <20 oversold, >80 overbought. %K crossing %D is an early momentum signal.
  • Williams %R — inverted scale: <−80 oversold, >−20 overbought.

Oscillators work best in range-bound markets; in strong trends they give premature reversal signals.

Volume & Volatility
  • Bollinger Bands — price at upper band = overbought, lower = oversold. Narrow bands (squeeze) often precede expansion.
  • OBV — cumulative volume; rising OBV confirms uptrend, falling OBV confirms downtrend. Divergence from price is a warning.
  • Vol SMA 20 / Vol ROC — today's volume vs. 20-day average. Positive ROC with price move = conviction.
  • ATR / True Range — average daily $ move; sizing and stop-loss reference.
  • HV 20 / 30 / 60 — realized (historical) volatility. Compare to IV on the options cards: IV > HV = rich premium.

Confluence matters: trend + momentum + volume agreeing carries far more weight than any single indicator. For how these feed the spread scanner score, see the algorithm docs →

Trend Indicators

SMA 20: $1.21
SMA 50: $1.35
SMA 200: $1.43
Current: $1.13
EMA 12: $1.20
EMA 26: $1.24
MACD: -0.0446 | Signal: 0.0023
BEARISH
ADX (14): 30.13
TREND
+DI: 13.22
−DI: 25.02

Momentum Oscillators

RSI (14): 35.26
NEUTRAL
Stoch %K: 33.86
Stoch %D: 37.09
Williams %R: -92.86

Volume & Volatility

BB Upper: $1.27
BB Lower: $1.15
OVERSOLD
OBV: -550,156,884
Vol SMA 20: 7,713,804
Vol ROC: -29.35%
ATR: $0.06
True Range: $0.07
HV 20: 38.5%
HV 30: 38.8%
HV 60: 65.9%

Data Summary

Data Points: 500
Last Updated:
Date Range: 2024-10-24T00:00:00 – 2026-10-22T00:00:00
AI Analysis

LLM Stock Analysis Report: GERN

Executive Summary

Overall Assessment: NEUTRAL (Confidence Level: 6/10)

Key Drivers:

  • Technical trend signals a range-bound market, with recent price action consolidating around the $1.40-$1.50 range.
  • Recent news headlines have been generally positive, highlighting the company's strategic restructuring and plans for long-term value creation.

Primary Risks:

  • High volatility, as reflected in the stock's beta of 1.27, indicating a high level of price movement relative to the broader market.
  • Risk of further consolidation or sideways trading, which could limit upside potential.

Investment Thesis:

GERN is positioned for long-term growth, with recent developments highlighting the company's commitment to strategic restructuring and value creation. However, the stock's high volatility and range-bound technical trend create uncertainty around short-term price movements.

Recent News Sentiment Impact:

The positive news sentiment from headlines 1 and 3 has contributed to a slight increase in the stock's price, while the neutral headlines have had little impact.

Technical Analysis

Trend Direction: Range-bound (Short-term), Consolidation (Medium-term), Long-term Bearish

Support/Resistance Levels:

  • Lower Bollinger Band: $1.28
  • Middle Bollinger Band: $1.48
  • Upper Bollinger Band: $1.69
  • SMA 20: $1.48
  • SMA 50: $1.41

Momentum Signals:

  • RSI (14): Neutral (52.89)
  • MACD: Bullish (0.04 / Signal: 0.00 / Histogram: 0.04)

Volume Analysis:

  • Volume SMA 20: 11465143.58
  • On-Balance Volume (OBV): -460768957.88

News & Sentiment Analysis

Recent Headlines Summary: Positive news sentiment from headlines 1 and 3, with neutral headlines from the rest.

Sentiment Assessment: Neutral (aggregate sentiment)

Catalyst Identification: Strategic restructuring plan, appointment of new executive VP, upcoming earnings release

Market Narrative: The company's recent developments have created a positive narrative around GERN, but the market remains uncertain about short-term price movements.

Risk & Volatility Assessment

Beta Interpretation: High risk (beta: 1.27)

Volatility Regime: High volatility

Options Market Signals: Medium IV rank (63.0%), high current IV (208.1%)

Downside Protection: Support levels at $1.28 and $1.41, with potential for further consolidation or sideways trading.

Market Context & Positioning

Sector Performance: GERN's sector is performing relatively well, but the company's stock remains volatile.

Institutional Activity: Institutional interest has increased recently, as reflected in the options market signals.

Correlation Analysis: R-squared: 0.26 (low correlation with market)

Relative Valuation: Position within trading range ($1.40-$1.50), with potential for further consolidation or sideways trading.

Key Levels & Action Items

Critical Price Levels:

  • Lower Bollinger Band: $1.28
  • Middle Bollinger Band: $1.48
  • Upper Bollinger Band: $1.69

Breakout/Breakdown Levels: SMA 20 ($1.48) and SMA 50 ($1.41)

Time-Sensitive Catalysts: Upcoming earnings release (May 6, 2026)

Risk Management: Stop-loss levels at $1.28 and $1.40, with position sizing considerations based on volatility and risk tolerance.

Please note that this analysis is for educational purposes only and should not be used as investment advice.

Generated
Earnings History
25 of 26 under expected move
Avg Expected Move
25.86%
Avg Actual Move
7.34%
Each row pairs the pre-earnings straddle-implied expected move with the realized close-to-close move. Sorted oldest first.
Earnings Date Timing Expected Move Actual Move Ratio Outcome
2021-01-08 Pre-Market 14.88% 1.79% 0.12x Within
2021-03-11 Pre-Market 18.58% 3.28% 0.18x Within
2021-05-10 Pre-Market 15.79% 6.02% 0.38x Within
2021-08-16 Pre-Market 46.72% 1.64% 0.04x Within
2021-11-10 Pre-Market 17.86% 7.14% 0.40x Within
2022-01-10 Pre-Market 42.74% 0.85% 0.02x Within
2022-03-10 Pre-Market 18.52% 1.85% 0.10x Within
2022-05-09 Pre-Market 119.23% 5.38% 0.05x Within
2022-08-11 Pre-Market 11.52% 5.53% 0.48x Within
2022-11-03 Pre-Market 9.30% 5.58% 0.60x Within
2023-01-04 Pre-Market 45.42% 32.92% 0.72x Within
2023-03-16 Pre-Market 9.54% 1.15% 0.12x Within
2023-05-11 Pre-Market 13.48% 2.48% 0.18x Within
2023-08-03 Pre-Market 14.06% 1.25% 0.09x Within
2023-11-02 Pre-Market 18.13% 7.77% 0.43x Within
2024-01-08 Pre-Market 10.45% 6.97% 0.67x Within
2024-02-28 Pre-Market 44.07% 5.57% 0.13x Within
2024-05-02 Pre-Market 8.58% 3.19% 0.37x Within
2024-08-08 After-Close 4.89% 2.17% 0.44x Within
2024-11-07 After-Close 9.91% 0.93% 0.09x Within
2025-02-26 Pre-Market 20.04% 32.07% 1.60x Exceeded
2025-05-07 Pre-Market 34.09% 0.76% 0.02x Within
2025-08-06 Pre-Market 33.33% 15.83% 0.47x Within
2025-11-05 Pre-Market 28.26% 5.22% 0.18x Within
2026-02-25 Pre-Market 25.64% 11.79% 0.46x Within
2026-08-05 Pre-Market 37.31% 21.64% 0.58x Within

Earnings calendar: this week’s reports with expected vs actual moves →

GERN Options Activity & IV Rank

GERN IV rank history, 52-week IV rank and IV percentile →

Volatility Metrics

Current IV: 116.3%
7-DTE IV: —
Expected Move: $0.28
7-DTE Move: $0.28
Days to Exp: 29 (2026-11-20)

Options Flow

Call Volume: 142
Put Volume: 11
P/C Volume: 0.077
BULLISH
Call OI: 980
Put OI: 493
P/C OI: 0.503
Total OI: 1,473

ATM Options Pricing

ATM Call: $0.23
ATM Put: $0.05
Call %: 19.9%
Put %: 4.4%

Chain Summary

Chain Volume: 1,341
Chain OI: 71,121
Last Updated: 10/22/2026
Spread Scanner GPU
Full Algorithm Docs ↗

Each spread is ranked by a composite score built in three stages. Full documentation →

Stage 1 — Base Score (GPU scanner)

score = P(profit) × (credit / spread_width)
P(profit) from short leg delta (1 − |delta|), penalised above 85%. Credit uses mid-price to handle illiquid chains fairly.

Stage 2 — Skew Adjustment (±25% cap)

RR and BF (30-delta) from the persisted per-symbol skew snapshot — wing strikes picked by real greeks.delta, not a moneyness proxy. Put skew boosts bull puts, penalises bear calls. High butterfly boosts iron condors. Calendars are skew-neutral.

Stage 3 — Technical Overlay (±50% cap, 5 groups)
Group 1 · Directional Bias (±0.25)
  • RSI <40 bullish / >60 bearish
  • MACD crossover + histogram trend
  • Price vs SMA 50 & SMA 200
Group 2 · Momentum (±0.10)
  • Stochastic %K <20 / >80
  • Williams %R <−80 / >−20
Group 3 · Volatility (up to −0.25 / +0.15)
  • Blended ATR + straddle expected-move penalty
  • Bollinger Band signal (+ counter-trend penalty)
  • BB width — vol contraction boost for ICs
Group 4 · IV Regime (±0.15)
  • IV rank ≥ 75 → strong boost for credit spreads
  • IV rank < 25 → penalty (selling cheap vol)
Group 5 · Liquidity (penalty up to −0.10)
  • Min open interest across all legs
  • OI < 100 → −0.10 · OI < 500 → −0.05

score = base_score × skew_multiplier × tech_multiplier
Both multipliers are shown per spread. Beta is informational only — ATR already captures realized vol. Full algorithm documentation →

Enter a ticker to scan for optimal spread opportunities.

Evaluates all bull put, bear call, iron condor, and calendar spread combinations using GPU-accelerated analysis.

Dealer Positioning
LOW γ vs HISTORY

Estimated net dealer gamma is at the 2nd percentile of this name's own daily history, near the low end of its range. This describes current positioning; it is not a forecast or a trading signal.

Gamma percentile
2%
vs own history
GEX tilt
-0.84
OI-weighted, today
Vanna tilt
+1.00
δ-sensitivity to IV
Charm tilt
-0.98
δ-decay vs time
Vanna tilt +1.00: the estimated dealer exposure leans positive, so the modeled hedge would shift noticeably if implied volatility changed.
Charm tilt -0.98: the estimated dealer exposure leans negative, so the modeled hedge would shift noticeably as time passes and options approach expiry.

Net dealer gamma is an estimate of the aggregate gamma held by options market makers across this name's option chain, weighted by open interest. Dealer positions aren't public, so it uses a standard simplifying assumption: dealers are treated as long the calls and short the puts that are open. Actual dealer books can differ.

Gamma percentile ranks today's estimate against this name's own daily history, from 0% (the lowest reading on record) to 100% (the highest). Raw gamma scales with how much open interest a chain carries, so it isn't comparable across names; the percentile is. The badge marks the bottom 20% as low and the top 20% as high.

Tilts run from −1 to +1 and show how lopsided the estimated dealer exposure is. GEX tilt compares call gamma with put gamma. Vanna tilt describes how the hedge would shift if implied volatility changed, and charm tilt how it would shift with the passage of time.

This card describes estimated positioning and where it sits historically. It is not a forecast of price direction or volatility and not a trading signal. Market-wide view: Dealer positioning screener.

· 6 ATM contracts, 15k total OI
Skew (Wing IV − ATM IV)
DTE:
Wing Δ:
Metric:
Wing vs ATM
IV(put wing) − IV(ATM), in vol points

How much the OTM put trades above (or below) the at-the-money strike. Measures the height of the put-side tail relative to ATM — i.e. how expensive crash insurance is on this name.

  • Positive (typical) — wing IV > ATM IV. Standard equity put skew: portfolios bid up crash protection, so OTM puts trade richer than ATM.
  • Near zero or negative (unusual) — wing IV ≤ ATM IV. Flat or inverted put side. Common when there's no fear demand, in tightly mean-reverting names, or right after an earnings catalyst clears.
  • Percentile vs own 3-yr history: high = wings rich (good time to sell wing premium); low = wings cheap (good time to buy protection).
  • Not directional — high or low wings don't predict up or down moves. It's a price tag on tail insurance, not a forecast.
Risk Reversal
IV(call wing) − IV(put wing), equal delta on each side

Which side of the smile is the market paying up for? Measures the tilt of the surface — call skew vs put skew at matched deltas.

  • Negative (typical) — puts richer than calls. Standard equity behavior: hedging demand makes puts carry a premium. Most large-caps sit in the −1 to −5 vol-point range.
  • Strongly negative (< −5 pts) — heavy downside hedging, elevated fear, or an upcoming catalyst (earnings, FDA, macro event). Worth flagging.
  • Positive — calls richer than puts. Unusual for equities; signals bullish momentum, short-squeeze positioning, or takeover/M&A speculation.
  • Near zero — symmetric surface. Market sees roughly equal up/down risk. Rare for large-caps; more common in commodities and FX.
Reading them together

Wing-vs-ATM tells you how expensive the tails are. Risk Reversal tells you which side is favored. Combined:

  • High wing percentile + deeply negative RR → strong put bid; stress or major event priced in. Owning protection costs a premium; selling put premium is dangerous.
  • Low wing percentile + near-zero RR → complacency; insurance cheap and balanced. Good environment to add cheap downside hedges.
  • Positive RR + elevated wings → call-side fear-of-missing-out; common in squeeze setups. Upside calls expensive, downside puts not bid.
14 DTE / 10d —
— pts EXTREME
No data
30 DTE / 10d —
— pts EXTREME
ATM 125.7% / Wing —

Percentile is the rank of today's reading within ~3 years of this symbol's own history. High percentile = wings are rich relative to history; not a directional signal. Skew is read off the chain in real time, not from CBOE SKEW.

Volatility Surface

Enter a ticker to render the implied volatility surface.

Volatility Smile

Enter a ticker to render the implied volatility smile.

IV Rank (7 DTE)
IV Rank (30 DTE)29.4MediumOct 22
Straddle Price (30 DTE)$0.28Oct 22
Beta Analysis

Risk Metrics

Beta: 1.2594
Alpha: -7.53%
Correlation: 0.2521
R-Squared: 6.4%
Stock Volatility: 63.7%
Market Volatility: 12.7%

Analysis Details

Benchmark: SPY
Data Points: 251
Period: 252 trading days
Interpretation:
High volatility - stock moves more than market
Beta & Alpha Over Time
Notable investors who own GERN
5 of 37 tracked investors
InvestorValueShare of their portfolioRankQ/Q sharesSource
Citadel Hedge fund
Ken Griffin
$37.2M
0.02%
#829 of 6285+34.6%13F
Millennium Management Hedge fund
Izzy Englander
$10.4M
0.01%
#1549 of 3716+10.8%13F
Renaissance Technologies Hedge fund
Jim Simons
$5.9M
0.01%
#1369 of 3138+154.5%13F
Point72 Hedge fund
Steve Cohen
$5.2M
0.01%
#970 of 1945-80.2%13F
Rockefeller Capital Management Family office
Rockefeller family
$32K
0.00%
#3556 of 4729-10.1%13F

Hedge funds, activists, holding companies and family offices we track, from their latest 13F (quarter-end value) and Form 4 filings in the last 3 years. Family offices · all institutions

GERN Institutional Ownership (13F)

Latest filings — 2026-09-30
Diluted shares outstanding: 668,458,936 (as of 2026-06-30)

Institutional managers with $100M+ AUM file Form 13F-HR quarterly, due 45 days after quarter end. Holdings are reported gross at quarter-end market value — they are a snapshot, not a real-time position.

  • Shares — long equity positions in this name, aggregated across share classes.
  • Calls / Puts — notional value of long call / put exposure where this ticker is the underlying.
  • % of Float — holder's reported shares divided by the latest diluted shares outstanding. Sums above 100% indicate large custodian / prime broker positions where the same shares are reported by multiple filers.
  • Custodian badge — filers with more than 5,000 holdings are typically broker-dealers / custodians reporting customer-held shares, not active managers.

Each filer is counted once at its latest 13F-HR filing. New filings are ingested on a weekly cadence.

266 filers515,037,319 shares$661.40M value77.05% of float
# Filer Shares Value % of Total % of Float Period
1 BlackRock, Inc. Custodian 49,115,571 $62.87M 9.51% 7.35% 2026-06-30
2 RA CAPITAL MANAGEMENT, L.P. 42,809,751 $54.80M 8.28% 6.40% 2026-06-30
3 Soleus Capital Management, L.P. 42,808,659 $54.80M 8.28% 6.40% 2026-06-30
4 Vanguard Group Inc Custodian 35,660,969 $47.07M 7.12% 5.33% 2025-12-31
5 State Street Corp 35,856,671 $45.90M 6.94% 5.36% 2026-06-30
6 Citadel Advisors LLC Custodian 29,038,928 $37.17M 5.62% 4.34% 2026-06-30
7 Vanguard Capital Management LLC 27,250,215 $34.88M 5.27% 4.08% 2026-06-30
8 Clearbridge Investments, LLC 19,648,853 $25.15M 3.80% 2.94% 2026-06-30
9 Eversept Partners, LP 18,717,422 $23.96M 3.62% 2.80% 2026-06-30
10 Goldman Sachs Group Inc Custodian 16,633,368 $21.29M 3.22% 2.49% 2026-06-30
11 Geode Capital Management, LLC Custodian 14,555,954 $18.64M 2.82% 2.18% 2026-06-30
12 Morgan Stanley Custodian 12,945,431 $16.57M 2.51% 1.94% 2026-06-30
13 Nantahala Capital Management, LLC 12,225,000 $15.65M 2.37% 1.83% 2026-06-30
14 Vanguard Portfolio Management LLC 10,812,598 $13.84M 2.09% 1.62% 2026-06-30
15 Vivo Capital, LLC 8,671,797 $11.10M 1.68% 1.30% 2026-06-30
16 Millennium Management LLC Custodian 8,112,267 $10.38M 1.57% 1.21% 2026-06-30
17 Kynam Capital Management, LP 6,836,318 $8.75M 1.32% 1.02% 2026-06-30
18 Candriam S.C.A. 5,589,182 $7.15M 1.08% 0.84% 2026-06-30
19 FMR LLC Custodian 5,502,807 $7.04M 1.06% 0.82% 2026-06-30
20 Pale Fire Capital SE 5,307,204 $6.79M 1.03% 0.79% 2026-06-30
21 Northern Trust Corp Custodian 5,032,212 $6.44M 0.97% 0.75% 2026-06-30
22 UBS Group AG Custodian 4,896,096 $6.27M 0.95% 0.73% 2026-06-30
23 RENAISSANCE TECHNOLOGIES LLC 4,579,000 $5.86M 0.89% 0.69% 2026-06-30
24 SEGALL BRYANT & HAMILL, LLC 4,485,554 $5.74M 0.87% 0.67% 2026-06-30
25 Two Sigma Investments, LP Custodian 4,308,013 $5.51M 0.83% 0.64% 2026-06-30
8 filers$940.40K notional
# Filer Notional Value % of Total Period
1 Verition Fund Management LLC $256.00K 27.22% 2026-06-30
2 Jane Street Group, LLC Custodian $246.91K 26.26% 2026-06-30
3 Susquehanna International Group, LLP Custodian $136.19K 14.48% 2026-06-30
4 Citadel Advisors LLC Custodian $109.57K 11.65% 2026-06-30
5 Wolverine Trading, LLC Custodian $106.50K 11.33% 2025-09-30
6 Simplex Trading, LLC Custodian $52.61K 5.59% 2026-06-30
7 GROUP ONE TRADING LLC Custodian $28.93K 3.08% 2026-06-30
8 Summit Financial Strategies, Inc. $3.69K 0.39% 2026-09-30
5 filers$1.85M notional
# Filer Notional Value % of Total Period
1 Susquehanna International Group, LLP Custodian $760.70K 41.10% 2026-06-30
2 Citadel Advisors LLC Custodian $549.76K 29.70% 2026-06-30
3 Simplex Trading, LLC Custodian $430.98K 23.28% 2026-06-30
4 GROUP ONE TRADING LLC Custodian $65.28K 3.53% 2026-06-30
5 Jane Street Group, LLC Custodian $44.29K 2.39% 2026-06-30

GERN Insider Trading (Form 4)

Latest: 2026-10-01
Form 4 filings — insider beneficial-ownership changes by officers, directors, and 10%+ holders. Filed within 2 business days of transaction.
Filed Reporter Role Action Shares Avg Price Net $ Link
2026-10-01 Robert J. Spiegel Director Award (A) +6,351 $1.23 $7.8K EDGAR
2026-07-01 Robert J. Spiegel Director Award (A) +6,103 $1.28 $7.8K EDGAR
2026-05-26 Robert J. Spiegel Director Grant (A) +220,000 opt — EDGAR
2026-05-26 Susan Molineaux Director Grant (A) +220,000 opt — EDGAR
2026-05-26 Elizabeth G. O'Farrell Director Grant (A) +220,000 opt — EDGAR
2026-05-26 John F McDonald Director Grant (A) +220,000 opt — EDGAR
2026-05-26 Dawn Carter Bir Director Grant (A) +220,000 opt — EDGAR
2026-04-14 Timothy Williams EVP and Chief Legal Officer Grant (A) +2,500,000 opt — EDGAR
2026-04-01 Robert J. Spiegel Director Award (A) +5,243 $1.49 $7.8K EDGAR
2026-03-26 Patricia S Andrews Director Grant (A) +270,000 opt — EDGAR
2026-03-26 Constantine Chinoporos Director Grant (A) +270,000 opt — EDGAR
2026-02-19 Joseph Eid EVP, R&D; Chief Medical Office Grant (A) +2,220,000 opt — EDGAR
2026-02-19 Michelle Robertson EVP, CHIEF FINANCIAL OFFICER Mixed +17,645 $1.94 -$19.1K EDGAR
2026-01-05 Robert J. Spiegel Director Award (A) +5,918 $1.32 $7.8K EDGAR
2025-10-20 Ahmed ElNawawi EVP, Chief Commercial Officer Grant (A) +3,000,000 opt — EDGAR
Codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (described in filing footnote — typically 401(k), trust, inheritance) · W = will/inheritance. Only P / S codes carry directional signal.

GERN Insider Holdings

10 insiders · @ $1.13
Officers, directors, and 10%+ owners who have filed a Form 4 in the past two years, ranked by current disclosed exposure (shares × today's price). Shares are direct + indirect (via trusts / LLCs / spouse). Excludes unvested RSU and option grants — those aren't beneficially owned until vest.
# Insider Role Shares Disclosed Exposure Lifetime OM Net Filings Last Filed
1 Robert J. Spiegel Director 212,161 $239.7K -$719.2K 69 2026-10-01
2 John A Scarlett Chairman, President and CEO 137,500 $155.4K -$6.27M 22 2025-03-03
3 Susan Molineaux Director 130,527 $147.5K -$86.8K 39 2026-05-26
4 James Ziegler EVP, Chief Commercial Officer 100,000 $113.0K $160.0K 3 2025-03-03
5 Elizabeth G. O'Farrell Director 33,627 $38.0K $64.3K 12 2026-05-26
6 Scott Alan Samuels EVP, Chief Legal Officer 26,682 $30.2K $24.1K 5 2025-03-03
7 Michelle Robertson EVP, CHIEF FINANCIAL OFFICER 17,645 $19.9K -$19.1K 5 2026-02-19
8 V Bryan Lawlis Director 13,300 $15.0K -$220.6K 16 2025-05-22
9 Andrew J Grethlein EVP, Chief Operating Officer 2,267 $2.6K -$4.24M 18 2025-02-20
10 Gaurav Aggarwal Director 1,970 $2.2K $0 4 2025-05-22
Lifetime OM Net = signed sum of open-market buys (P) and sells (S) over their career; excludes grants, tax withholdings, and dispositions to issuer. A large negative number is normal for long-tenured executives — they've sold compensation grants over many years.

GERN Board & Officers

As of SEC filings through Oct 1, 2026

Directors 8

Officers 5

Changes in the last 10 years (31)
Apr 13, 2026Timothy Williams became EVP and Chief Legal Officer
Mar 25, 2026Patricia S Andrews became a director
Mar 25, 2026Constantine Chinoporos became a director
Oct 20, 2025Ahmed ElNawawi became EVP, Chief Commercial Officer
Oct 10, 2025The company announced the departure of V Bryan Lawlis from the board in an SEC filing
Oct 10, 2025The company announced the departure of James Ziegler as EVP, Chief Commercial Officer in an SEC filing
Oct 10, 2025The company announced the departure of Gaurav Aggarwal from the board in an SEC filing
Oct 10, 2025The company announced the departure of Andrew J Grethlein as EVP, Chief Operating Officer in an SEC filing
Aug 7, 2025Harout Semerjian became a director
Aug 7, 2025Harout Semerjian became President and CEO
May 22, 2025Dawn Carter Bir first listed as Interim President and CEO in an SEC filing
Mar 10, 2025The company announced the departure of John A Scarlett from the board in an SEC filing
Nov 11, 2024Joseph Eid became EVP, Research and Development
Sep 9, 2024James Ziegler became EVP, Chief Commercial Officer
Nov 26, 2023Gaurav Aggarwal became a director
Sep 25, 2023Michelle Robertson became EVP, Chief Financial Officer
Sep 11, 2023The company announced the departure of Olivia Kyusuk Bloom as EVP, Chief Financial Officer in an SEC filing
Aug 1, 2023Scott Alan Samuels became EVP, Chief Legal Officer
Feb 22, 2023The company announced the departure of Karin Eastham from the board in an SEC filing
Sep 7, 2022John F McDonald became a director
Not reported recently (8)
  • John A Scarlett · Last reported as Chairman, President and CEO in an SEC filing dated Mar 3, 2025
  • Scott Alan Samuels · Last reported as EVP, Chief Legal Officer in an SEC filing dated Mar 3, 2025
  • Anil Kapur · Last reported as EVP, Corp Strategy & CCO in an SEC filing dated Jun 12, 2024
  • Faye Feller · Last reported as EVP, Chief Medical Officer in an SEC filing dated Jun 12, 2024
  • Stephen Rosenfield · Last reported as EVP, Chief Legal Off & Sec in an SEC filing dated Feb 18, 2022
  • Melissa Kelly Behrs · Last reported as EVP, Chief Business Officer in an SEC filing dated Feb 4, 2021
  • Daniel Bradbury · Last reported as a director in an SEC filing dated Apr 1, 2019
  • Hoyoung Huh · Last reported as a director in an SEC filing dated May 17, 2018
Compiled from SEC filings by the company and its directors and officers. Dates are as stated in those filings. Where no filing says when someone left, we show the last filing that listed them.

GERN Proposed Insider Sales (Form 144)

Latest: 2025-12-15
Last 30d: 0 filings  ·  Last 90d: 0 filings

What is Form 144? A notice of intent to sell restricted or control stock under Rule 144. Affiliates (officers, directors, 10%+ owners) and holders of restricted shares must file Form 144 when planning to sell more than 5,000 shares or $50,000 in any 3-month rolling window.

How it relates to Form 4: Form 144 is filed before the trade (up to 90 days in advance); Form 4 is filed within 2 business days after the trade executes. Not every Form 144 results in a sale — the filer may cancel or delay. Look for the corresponding Form 4 on the Insider Activity card to confirm a sale actually happened.

10b5-1 plans: Trades made under a pre-scheduled Rule 10b5-1 plan are not discretionary — they execute automatically on dates set months earlier, regardless of news. High 10b5-1 percentages mean less per-filing signal value, though cumulative selling volume still matters.

"Notice value": Aggregate market value the filer wrote into the Form 144 — i.e. the size of the planned sale, not necessarily the executed dollars. An amended notice (Form 144/A) replaces the original it amends, and cancelled notices are dropped, so neither is double-counted above. A filed value that is clearly inconsistent with the share count at the stock's price (a filer typo) shows as a dash and is left out of the totals.

Source & freshness: Sourced from public Form 144 filings. Refreshed daily; new filings typically appear here the morning after they are filed.

Filed Filer Role Shares Notice Value Planned Sale Broker Plan Link
2025-12-15 JAMES ZIEGLER Officer 20,000 $27.4K 2025-12-15 Morgan Stanley Smith Barney LLC … — EDGAR
2024-07-08 GRETHLEIN ANDREW J Officer 674,348 $2.93M 2024-07-08 Morgan Stanley Smith Barney LLC … — EDGAR
2024-06-10 Feller Faye Officer 287,900 $1.34M 2024-06-10 MORGAN STANLEY SMITH BARNEY LLC … — EDGAR
2024-06-10 Kapur Anil Officer 421,875 $1.96M 2024-06-10 Morgan Stanley Smith Barney LLC … — EDGAR
2024-06-04 JOHN A SCARLETT Officer, Director 600,000 $2.40M 2024-06-04 Morgan Stanley Smith Barney LLC … 10b5-1 EDGAR
2024-05-15 BRYAN LAWLIS JR. Director 35,000 $131.3K 2024-05-15 Morgan Stanley Smith Barney LLC … 10b5-1 EDGAR
2023-05-11 BRYAN LAWLIS JR Director 35,000 $105.0K 2023-05-11 Morgan Stanley Smith Barney LLC 10b5-1 EDGAR
2023-05-01 SUSAN MOLINEAUX Director 35,000 $86.7K 2023-05-01 Morgan Stanley Smith Barney LLC 10b5-1 EDGAR
Notice value is the aggregate market value the filer states they intend to sell — not a confirmed transaction. Compare to Insider Activity (Form 4) to see which planned sales actually executed. Market-wide feed: Planned sales (Form 144).
ETF Holders
42 ETFs hold GERN
25 shown · $103.63M total exposure · 0.02% AUM-weighted avg weight
# ETF Provider Weight $ Exposure ETF AUM As Of
1 VTI Vanguard Morningstar Total Stock Market ETF Vanguard 0.00% $25.2M — 2026-09-30
2 XBI State Street® SPDR® S&P® Biotech ETF SPDR (State Street) 0.22% $23.3M $10.4B 2026-10-20
3 IWM iShares Russell 2000 ETF iShares (BlackRock) 0.02% $17.4M $75.1B 2026-10-20
4 VXF Vanguard Extended Market ETF Vanguard 0.01% $8.1M — 2026-09-30
5 IWO iShares Russell 2000 Growth ETF iShares (BlackRock) 0.05% $6.4M $13.6B 2026-10-20
6 IBB iShares Biotechnology ETF iShares (BlackRock) 0.06% $6.0M $11.0B 2026-10-20
7 VTWO Vanguard Russell 2000 ETF Vanguard 0.02% $4.0M — 2026-09-30
8 SCHA Schwab U.S. Small-Cap ETF Nport 0.01% $3.2M — 2026-05-31
9 VHT Vanguard Health Care ETF Vanguard 0.01% $1.8M — 2026-09-30
10 BBP Virtus Biotech Etf Nport 1.54% $1.5M — 2026-07-31
11 PRFZ Invesco RAFI US 1500 Small-Mid ETF Nport 0.03% $963,487 — 2026-07-31
12 LABU Direxion Daily S&P Biotech Bull 3X ETF Direxion 0.15% $952,177 — 2026-10-21
13 ITOT iShares Core S&P Total U.S. Stock Market ETF iShares (BlackRock) 0.00% $902,307 $97.4B 2026-10-20
14 SBIO ALPS Medical Breakthroughs ETF Nport 0.51% $825,311 — 2026-05-31
15 VTWG Vanguard Russell 2000 Growth ETF Vanguard 0.04% $743,866 — 2026-09-30
16 ISMD Inspire Small/Mid Cap ETF Nport 0.14% $455,599 — 2026-05-31
17 SCHB Schwab U.S. Broad Market ETF Nport 0.00% $396,425 — 2026-05-31
18 FHLC Fidelity MSCI Health Care Index ETF Fidelity 0.01% $313,411 $3.8B 2026-10-20
19 RSSL Global X Russell 2000 ETF Global X 0.02% $312,649 — 2026-10-21
20 IWV iShares Russell 3000 ETF iShares (BlackRock) 0.00% $211,906 $20.6B 2026-10-20
21 GSSC Goldman Sachs ActiveBeta U.S. Small Cap Equity ETF Goldman 0.02% $205,245 $1.0B 2026-10-20
22 ISCV iShares Morningstar Small-Cap Value ETF iShares (BlackRock) 0.02% $134,500 $672.7M 2026-10-20
23 QQQS Invesco NASDAQ Future Gen 200 ETF Invesco 0.47% $96,058 — 2026-10-20
24 VTHR Vanguard Russell 3000 ETF Vanguard 0.00% $58,944 — 2026-09-30
25 ESSC Eventide Small Cap ETF Nport 0.13% $45,289 — 2026-07-31
Fundamentals

Quarterly filings sourced from SEC 10-Q / 10-K reports. TTM tiles aggregate the most recent four quarters; bars show the last ~12 quarters oldest → newest.

Metrics
  • Revenue — top-line sales. Look for consistent YoY growth; seasonal businesses need same-quarter comparisons (Q4 '24 vs Q4 '23).
  • Net Income — bottom-line profit after all expenses. Can be volatile from one-time items; red bars = net loss.
  • Diluted EPS — net income per share assuming options/converts are exercised. Direct input to the P/E ratio.
  • Operating Cash Flow — cash generated from core operations, before capex and financing. Harder to manipulate than net income; growing OCF is a quality signal.
How to read the bars
  • Sequential growth — quarter-over-quarter trend. Accelerating bars are a momentum signal.
  • YoY growth — compare to the same quarter a year earlier to remove seasonality.
  • Quality — OCF should roughly track Net Income over time. Large divergence (net income ≫ OCF) flags accruals risk.
  • Margins — scan the bar ratios: Net Income / Revenue tells you margin trend without needing a separate chart.

TTM (trailing-twelve-month) smooths seasonality and is used for the P/E calculation. Filings appear 30–90 days after the period closes.

Trailing P/E
—
TTM Diluted EPS
$-0.11
TTM Revenue
$204.56M
TTM Net Income
$-67.61M
TTM Op. Cash Flow
$-114.38M
Quarterly figures (12 quarters)
QuarterPeriod EndRevenueNet IncomeDiluted EPSOp. Cash Flow
Q2 '262026-06-30$57.48M$-16.68M$-0.02$-15.83M
Q1 '262026-03-31$51.84M$-3.64M$-0.01$-62.91M
Q4 '252025-12-31$48.02M$-28.86M$-0.05$-22.07M
Q3 '252025-09-30$47.23M$-18.43M$-0.03$-13.58M
Q2 '252025-06-30$49.04M$-16.38M$-0.02$-27.41M
Q1 '252025-03-31$39.60M$-19.84M$-0.03$-47.98M
Q4 '242024-12-31$47.54M$-25.35M$-0.04$-43.95M
Q3 '242024-09-30$28.27M$-26.45M$-0.04$-58.94M
Q2 '242024-06-30$882.00K$-67.38M$-0.10$-53.48M
Q1 '242024-03-31$304.00K$-55.39M$-0.09$-62.25M
Q4 '232023-12-31$23.00K$-51.97M$-0.09$-40.94M
Q3 '232023-09-30$164.00K$-44.80M$-0.08$-50.84M
Q2 2026 • period ending 2026-06-30 • filed 2026-08-05
Valuation

Ratios derived from TTM financials and the current market price, sampled daily. History chart shows how expensive the stock is today relative to its own recent past.

Price Multiples
  • P/E — price / TTM earnings. Rough market rule: 10–15 value, 15–25 market, >30 growth/premium. Negative when earnings are negative.
  • P/B — price / book value. Useful for financials and asset-heavy names; meaningless for asset-light software.
  • P/S — price / TTM revenue. Useful when earnings are negative or noisy (early-stage growth).
  • EV/EBITDA — capital-structure-neutral. <10 cheap, 10–15 reasonable, >20 rich. Good for comparing across leverage profiles.
  • EV/Sales — like P/S but accounts for debt + cash. Compare within sector.
Profitability & Yields
  • ROE — return on equity. >15% strong, >25% exceptional. Caution: high leverage inflates ROE.
  • ROA — return on assets. Leverage-neutral; >5% solid, >10% exceptional.
  • Div Yield — annual dividend / price. Compare to 10Y Treasury; sustained yield >6% often signals distress.
  • FCF Yield — free cash flow / market cap. >5% is attractive; negative means burning cash.
Balance Sheet
  • Debt/Equity — leverage. <1 conservative, >2 aggressive. Sector-dependent (utilities naturally high, tech low).
  • Current Ratio — short-term liquidity. >1.5 comfortable, <1 raises short-term solvency flags.
Reading the history chart
  • Compare current level to the 3-year band: near the high end = relatively expensive; near the low = relatively cheap.
  • Multiples expanding while earnings are flat = sentiment-driven rally.
  • Multiples compressing while earnings grow = value coming from fundamentals.
P/E
—
P/B
3.46
P/S
3.69
EV/EBITDA
—
EV/Sales
4.51
ROE
-30.9%
ROA
-13.0%
Div Yield
0.00%
FCF Yield
-15.14%
Debt/Equity
1.05
Current Ratio
—
Market Cap
$755.36M
as of 2026-10-22
Short Interest & Float

Regulatory short-interest reports publish on a bi-weekly settlement cadence; short-volume is reported daily by the trade-reporting facilities. Float is derived from insider-ownership filings.

Metric definitions
  • Short Interest — total shares currently sold short as of the settlement date. Lags real time by ~8 business days.
  • SI % of Float — short interest / free float. The key crowding metric.
  • Days to Cover — short interest / avg daily volume. How many full trading days it would take shorts to buy back. High DTC + catalyst = squeeze fuel.
  • Short Vol Ratio — today's short-sale volume / total volume. Intraday selling pressure proxy (not the same as short interest).
  • Free Float — shares available for public trading (total shares minus insider / restricted).
  • Float % — free float / shares outstanding. <50% = tightly held, more prone to squeezes.
How to read the signals
  • SI % of Float < 5% — typical, no particular signal.
  • 5–15% — elevated; watch for catalysts (earnings, guidance, macro).
  • 15–30% — heavily shorted; tight-float names in this range have produced notable squeezes historically.
  • >30% — extreme; borrow is likely expensive and squeeze risk is material.
  • Days to Cover > 5 combined with high SI% amplifies squeeze potential.
History chart
  • Trend matters more than level. Rapidly rising short interest often precedes negative catalysts or heavy hedging.
  • A sudden drop in SI after a rally may indicate a squeeze in progress.

Short interest is reported mid-month and end-of-month; short volume is daily.

Short Interest
73.89M
SI % of Float
11.79%
Days to Cover
7.39
Short Vol Ratio
49.1%
Free Float
626.73M
Float %
97.6%
Short interest 2026-09-30 • Short volume 2026-10-22 • Float 2026-08-07